

Outcomes Research in Psoriasis and Psoriatic Arthritis Using Large Databases and Research Networks: A Report from the GRAPPA 2013 Annual Meeting

April W. Armstrong, Joel M. Gelfand, and Amit Garg

ABSTRACT. Advances in healthcare informatics have increased the ability to address real-world, clinically relevant questions using large databases. When examining data sources, researchers and clinicians need to consider data validity, potential sources of misclassification, whether the source is sufficiently powered to detect clinically relevant differences, ability to obtain longitudinal data, containment of patients within a database, and ability to obtain structured point-of-care data. Population-based databases create opportunities for characterizing natural history of psoriatic diseases, conducting comparative effectiveness research, determining comorbidities, and providing epidemiology-based rational approaches to mechanistic investigations. Herein, we discuss the major data sources for clinical research in psoriasis, including electronic medical records, research networks, disease registries, and others. (J Rheumatol 2014;41:1233–6; doi:10.3899/jrheum.140178)

Key Indexing Terms:

PSORIASIS
REGISTRY

PSORIATIC ARTHRITIS
ELECTRONIC MEDICAL RECORDS

OUTCOMES RESEARCH
LARGE DATABASE RESEARCH

At the 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Toronto, Ontario, Canada, members explored opportunities for outcomes research using large databases and research networks. To address real-world, clinically relevant questions in psoriasis and psoriatic arthritis (PsA), we examined the advances in healthcare informatics and the features of data sources (e.g., strengths, limitations, and appropriateness for a given research question) that enable us to conduct such investigations.

How to Evaluate Large Databases for Research in Psoriasis and Psoriatic Arthritis

When examining data sources, researchers and clinicians must consider 6 major factors:

(1) Are the data valid? Do they accurately represent the

From the Department of Dermatology, University of Colorado, Denver, Colorado; University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania; and the Department of Dermatology, Hofstra North Shore LIJ School of Medicine, Hempstead, New York, USA.

Dr. Gelfand was supported by a grant from US National Institute of Arthritis and Musculoskeletal and Skin Diseases (K24 AR 064310).

A.W. Armstrong, MD, MPH, Vice Chair for Clinical Research, Associate Professor of Dermatology, Director, Dermatology Clinical Trials and Outcomes, Director, Psoriasis Care and Research, Department of Dermatology, Colorado Health Outcomes Program, University of Colorado Denver, School of Medicine; J.M. Gelfand, MD, MSCE, University of Pennsylvania, Perelman School of Medicine; A. Garg, MD, Associate Professor, Department of Dermatology, Hofstra North Shore LIJ School of Medicine.

Address correspondence to Dr. Armstrong, Colorado Health Outcomes Program, University of Colorado Denver, School of Medicine, Mail Stop F443, 13199 E. Montview Blvd., Suite 300, Aurora, Colorado 80045, USA. E-mail: aprilarmstrong@post.harvard.edu

information sought by the investigators? What are potential sources of misclassification? Is misclassification differential? (2) Are the data sufficiently powered to detect a clinically relevant effect? Sample sizes must be sufficiently large to detect small, but clinically relevant, differences. Data collected from diverse practice settings may increase the generalizability of the findings.

(3) Can patients be followed longitudinally? The ability to ascertain time-series data on a population is critical for understanding disease progression and following response to treatment over time.

(4) Are patients contained within the same healthcare system? When patients move in and out of health systems that do not have shared or linked health records, clinically relevant events occurring outside the examined health system could be missed.

(5) Does the database incorporate various perspectives, e.g., conventional health-provider, patient-reported outcomes, and robust linkage to pharmacy, laboratory, and pathology data?

(6) Does the database have efficient, point-of-care data entry? Can novel or confounding outcome measures (e.g., smoking, obesity) be easily incorporated into the data collection process? A key factor is the ability to engage users to enter structured, clinically relevant information efficiently.

Examples of Data Sources and Their Application in Psoriasis and Psoriatic Arthritis Research

Population-based databases create opportunities for various types of investigative endeavors, including characterizing

natural history of psoriatic diseases, conducting comparative effectiveness research, determining comorbidities, and providing epidemiology-based rational approaches to mechanistic investigations¹. However, depending on the purpose and scope of the database, they are variably suited to answer specific research questions. Described below are major types of data sources available for clinical research and their associated advantages and disadvantages.

Electronic medical records (EMR). EMR have been widely adopted in the past few years and present a remarkable opportunity for clinicians to enter visit information at point of care; laboratory and imaging data are also readily available. However, challenges exist for extracting EMR data for population research: medical records housed on different electronic health record platforms create difficulties for combining data; and despite technological advances such as natural language processing, extracting valid responses from nonstructured data elements is problematic². Despite these challenges, however, real-world data obtained at point of care presents appealing opportunities for generating “large” data to power hypothesis-driven, patient-oriented research.

In the simplest form, a single practitioner through his or her practice generates clinical care data based on individual patient encounters. Alternatively, a single institution can combine patient data from multiple practitioners to create larger datasets that reflect more diverse patient populations and a wider range of clinician practice patterns. In multi-institutional or multicentered datasets, data are combined from several groups that usually share a common EMR platform.

For example, in the United States, several EMR systems exist. To date, EMA is the largest dermatology-specific EMR system in the United States³, whereas Epic⁴ and Cerner⁵ are non-specialty-specific EMR systems used widely in academic institutions and healthcare maintenance organizations. The Veteran’s Affairs⁶ Healthcare System uses a centralized EMR for all its US sites, which makes extraction of EMR data possible for research across large populations. There are different approaches to validating diagnostic codes for psoriasis and PsA, including in-person examination by dermatologists or rheumatologists, chart reviews, and retrospective surveys of practitioner and patients. Validation of diagnostic codes for psoriasis and PsA was performed in the Kaiser Permanente EMR as well as databases from the UK, including the General Practice Research Database and The Health Improvement Network (THIN^{7,8,9,10}). THIN, for example, allows investigators to obtain additional information such as body surface area affected by psoriasis by surveying the patient’s general practitioner^{11,12}. Thus, validation of outcomes, examination of data availability, extraction of structured data, and handling of unstructured data are important considerations when using data extracted from EMR.

Research networks and disease registries. While research networks and disease registries differ in scope, mission, and patient population, many were created to evaluate effectiveness and monitor safety of systemic medications among patients with moderate-to-severe psoriasis and/or PsA. Research networks and disease registries often collect granular and relevant data, but their setup and sustainability costs continue to be challenging.

Psonet¹³ is a European system of independent registries that monitors longterm efficacy of systemic medications for treatment of psoriasis¹⁴. Currently participating countries include the UK, Portugal, Spain, France, The Netherlands, Germany, Switzerland, Italy, Denmark, Sweden, Israel, and Australia. Psonet researchers collect data on effectiveness and adverse events related to biologics or other systemic medications in patients with psoriasis and/or PsA. Similarly, the German Psoriasis Registry collects data from patients with psoriasis and PsA to determine the longterm safety, tolerability, and efficacy of biologics and other systemic medications that are used in Germany¹⁵. The Australasian Psoriasis Registry (APR) established an analogous database of patients with psoriasis in Australia, New Zealand, and New Guinea¹⁶. The Dermatology Clinical Effectiveness Research Network in the United States is a system of multiple dermatology practices that conducts clinical research studies of comparative effectiveness to help inform treatment decisions, and currently maintains a database of over 1700 patients with moderate to severe psoriasis evaluated during routine clinical followup care^{17,18,19,20,21,22}.

Members of the International Psoriasis and Arthritis Research Team (IPART), which includes several groups in Canada and the United States, have developed a large database of well-phenotyped patients with PsA and/or psoriasis based on an observational cohort at the University of Toronto. The international collaboration aims to use the IPART database to perform genome-wide association studies, in addition to studying disease progression, severity, and comorbidities²³.

Government-mandated postmarketing registries can provide valuable data regarding longterm medication safety^{21,24}, and many registries also collect additional information to help inform comorbidities research. For example, the Psoriasis Longitudinal Assessment and Registry is a 10-year study evaluating the longterm safety of the biologic therapies ustekinumab and infliximab²⁴ in 12,000 US patients with moderate to severe plaque psoriasis. Researchers are also collecting other important outcomes data, e.g., patient quality of life, clinical outcomes, and comorbidities.

While a number of other registries and research networks exist that are not specific to psoriasis or PsA, they often include those populations in their mission of evaluating patients receiving biologic treatments or those with rheumatologic diseases. The British Association of Dermatologists

Biologic Interventions Registry (BADBIR) houses observational data from a large cohort of patients with psoriasis, rheumatologic conditions, and/or inflammatory bowel diseases being treated with biologics or other systemic medications to determine the longterm safety of biologics in the UK and Ireland²⁵. Another example is the Consortium of Rheumatology Researchers of North America (CORRONA), a registry that houses data from patients with rheumatologic conditions (primarily rheumatoid arthritis, but also PsA) from the United States²⁶.

Other data sources: National healthcare data and surveys, administrative databases, and crowdsourced data. Various regions of the world have different standards for collecting population-based healthcare data. For example, whereas nationalized and centralized databases for healthcare records exist in countries such as Israel²⁷, Denmark²⁸, and Taiwan²⁹, many countries lack such databases. In the United States, the Centers for Medicare and Medicaid Services house centralized data for individuals ≥ 65 years as well as those enrolled in the Medicaid program (the federal healthcare program for those who cannot afford health insurance)³⁰. Other federally funded databases such as the National Ambulatory Medical Care Survey/National Hospital Ambulatory Medical Care Survey³¹ and National Health and Nutrition Examination Survey^{32,33,34,35} obtain nationally representative data, but their utility is limited by the number and type of questions specific to psoriasis and PsA. In the UK, practitioners have an incentive to put data into the Clinical Practice Research Datalink to yield more granular data for outcomes assessment and other research purposes³⁶.

Administrative and claims databases such as Truven Health Analytics MarketScan are helpful in providing aggregate data on diagnosis and medication use³⁷. However, those data are derived for the purposes of billing and may be more prone to misclassification that could threaten data validity.

Finally, crowdsourcing-generated data also provide valuable information^{38,39,40,41,42}. In healthcare research, crowdsourcing is the act of outsourcing data collection to patients. Potential advantages include recruitment of larger patient populations, lower cost for data collection, obtaining patient-centered perspectives, and the ability of patients to contribute through the Internet, providing ongoing opportunities for patients from diverse backgrounds to contribute to the collective patient experience.

The opportunities for conducting outcomes research using the various large databases and research networks are becoming more abundant. Aligning the research question with the appropriate database and analytical approach, however, is key to addressing clinically relevant questions appropriately. Although access to the various databases may be limited by cost and procedural challenges, the future for outcomes research in psoriasis and PsA is promising. With

continued improvements in healthcare informatics, creation of more psoriasis and psoriatic disease-specific research networks, and advancements in analytical approaches, we will be able to increasingly use real-world observational data to perform quality research that informs clinical decisions and improves patient outcomes.

REFERENCES

1. Armstrong AW, Reddy SB, Garg A. Novel approach to utilizing electronic health records for dermatologic research: developing a multi-institutional federated data network for clinical and translational research in psoriasis and psoriatic arthritis. *Dermatol Online J* 2012;18:2.
2. Ananthakrishnan AN, Cai T, Savova G, Cheng SC, Chen P, Perez RG, et al. Improving case definition of Crohn's disease and ulcerative colitis in electronic medical records using natural language processing: a novel informatics approach. *Inflamm Bowel Dis* 2013;19:1411-20.
3. EMA Dermatology [Internet. Accessed March 26, 2014.] Available from: www.modmed.com/dermatology-features
4. Epic. [Internet. Accessed March 26, 2014.] Available from: www.epic.com/software-index.php
5. Cerner acute care electronic medical record. [Internet. Accessed March 26, 2014.] Available from: www.cerner.com/solutions/Hospitals_and_Health_Systems/Acute_Care_EMR/
6. Weinstock MA, Bingham SF, Digiovanna JJ, Rizzo AE, Marcolivio K, Hall R, et al. Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. *J Invest Dermatol* 2012;132:1583-90.
7. Asgari MM, Wu JJ, Gelfand JM, Salman C, Curtis JR, Harrold LR, et al. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. *Pharmacoepidemiol Drug Saf* 2013;22:842-9.
8. Seminara NM, Abuabara K, Shin DB, Langan SM, Kimmel SE, Margolis D, et al. Validity of The Health Improvement Network (THIN) for the study of psoriasis. *Br J Dermatol* 2011;164:602-9.
9. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. *Arch Dermatol* 2005;141:1537-41.
10. Ogdie A, Langan S, Love T, Haynes K, Shin D, Seminara N, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. *Rheumatology* 2013;52:568-75.
11. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. *BMJ* 2013;347:f5961.
12. Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. *JAMA Dermatol* 2013;149:1173-9.
13. Psonet. European surveillance network to monitor the long term effectiveness and safety of systemic agents in the treatment of psoriasis [Internet. Accessed March 26, 2014.] Available from: www.psonet.eu/cms/
14. Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, et al. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. *Adv Ther* 2012; 29:620-34.
15. The German Psoriasis Registry (PsoBest) [Internet. Accessed March 26, 2014.]. Available from: www.psobest.de/
16. Australasian Psoriasis Registry (APR) [Internet. Accessed March 26, 2014.]. Available from: <https://psoriasis.asn.au/>
17. Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE,

- Weisman JD, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. *Arch Dermatol* 2012;148:487-94.
18. Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. *J Am Acad Dermatol* 2013;68:64-72.
 19. Callis Duffin K, Yeung H, Takeshita J, Krueger GG, Robertson AD, Troxel AB, et al. Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. *Br J Dermatol* 2014;170:672-80.
 20. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the national psoriasis foundation surveys, 2003-2011. *JAMA Dermatol* 2013;149:1180-5.
 21. Bhutani T, Wong JW, Bebo BF, Armstrong AW. Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. *JAMA Dermatol* 2013;149:717-21.
 22. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. *PLoS One* 2012;7:e52935.
 23. Gladman DD, Chandran V. Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future? *Curr Rheumatol Rep* 2011;13:346-52.
 24. Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. *J Drugs Dermatol* 2012;11:1210-7.
 25. British Association of Dermatologists Biologic Interventions Registry (BADBIR) [Internet. Accessed March 26, 2014.]. Available from: www.badbir.org/index.aspx.
 26. Consortium of Rheumatology Researchers of North America (CORRONA). [Internet. Accessed March 26, 2014.]. Available from: <http://corrna.com/p/index.html>.
 27. Dreither J, Freud T, Cohen AD. Psoriatic arthritis and diabetes: a population-based cross-sectional study. *Dermatol Res Pract* 2013;2013:580404.
 28. Ahlehoff O, Skov L, Gislason G, Lindhardsen J, Kristensen SL, Iversen L, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. *J Intern Med* 2013;273:197-204.
 29. Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. *J Dermatol Sci* 2011;63:40-6.
 30. Centers for Medicare and Medicaid Services. [Serial on the Internet. Accessed March 26, 2014.]. Available from: www.cms.gov/.
 31. Armstrong AW, Idriss N, Bergman H. Physician workforce for acne care in the United States, 2003 through 2005. *Arch Dermatol* 2009;145:1195-6.
 32. Johnson JA, Ma C, Kanada KN, Armstrong AW. Diet and nutrition in psoriasis: analysis of the National Health and Nutrition Examination Survey (NHANES) in the United States. *J Eur Acad Dermatol Venereol* 2014;28:327-32.
 33. Ma C, Schupp CW, Armstrong EJ, Armstrong AW. Psoriasis and dyslipidemia: a population-based study analyzing the National Health and Nutrition Examination Survey (NHANES). *J Eur Acad Dermatol Venereol* 2013 Aug 1 (E-pub ahead of print).
 34. Armstrong AW, Follansbee MR, Harskamp CT, Schupp CW. Psoriasis and Sexual Behavior in U.S. Women: an epidemiologic analysis using the National Health and Nutrition Examination Survey (NHANES). *J Sex Med* 2013;10:326-32.
 35. Armstrong AW, Harskamp CT, Schupp CW. Psoriasis and Sexual Behavior in Men: examination of the National Health and Nutrition Examination Survey (NHANES) in the United States. *J Sex Med* 2014;11:394-400.
 36. Clinical Practice Research Datalink (CPRD) [Internet. Accessed March 26, 2014.]. Available from: www.cprd.com/intro.asp
 37. Thomson Reuters [Internet. Accessed March 26, 2014.]. Available from: <https://marketscan.truvenhealth.com/marketscanportal>
 38. Parsi K, Chambers CJ, Armstrong AW. Cost-effectiveness analysis of a patient-centered care model for management of psoriasis. *J Am Acad Dermatol* 2012;66:563-70.
 39. Armstrong AW, Harskamp CT, Cheeney S, Schupp CW. Crowdsourcing in eczema research: a novel method of data collection. *J Drugs Dermatol* 2012;11:1153-5.
 40. Armstrong AW, Harskamp CT, Cheeney S, Schupp CW. Crowdsourcing for research data collection in rosacea. *Dermatol Online J* 2012;18:15.
 41. Armstrong AW, Harskamp CT, Cheeney S, Wu J, Schupp CW. Power of crowdsourcing: novel methods of data collection in psoriasis and psoriatic arthritis. *J Am Acad Dermatol* 2012;67:1273-81e9.
 42. Armstrong AW, Wu J, Harskamp CT, Cheeney S, Schupp CW. Crowdsourcing for data collection: a pilot study comparing patient-reported experiences and clinical trial data for the treatment of seborrheic dermatitis. *Skin Res Technol* 2013;19:55-7.